Frankfurt
25.02.25
08:05 Uhr
1,764 Euro
-0,056
-3,08 %
-3,08 %
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,762 | 1,812 | 25.02. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.02. | Crossject announces the reappointment of Patrick Alexandre and Isabelle Liebschutz as members of new, streamlined Executive Board | 71 | GlobeNewswire (Europe) | Dijon, FRANCE, February 12, 2025 - 0730 (CET) - Crossject (ISIN: FR0011716265; Euronext Growth: ALCJ), a specialty pharma company developing medicines harnessing its unique, award-winning needle-free... ► Artikel lesen | |
| 19.12.24 | Crossject confirms ZEPIZURE supply chain readiness with another successful ISO audit for Quality Management System | 78 | GlobeNewswire (Europe) |
Crossject successfully passes another ISO 13485 audit for sites in Dijon and Gray (France)Company is ramping up supply chain to prepare for commercialization in U.S. Dijon, France, December 19, 2024... ► Artikel lesen | |
| 11.12.24 | Crossject announces the pricing of its reserved capital increase and warrants issuance for an aggregate amount of EUR 7.2M | 2 | GlobeNewswire (USA) | ||
| 10.12.24 | Crossject launches reserved capital increase and warrants issuance for an aggregate amount of at least €7m | 1 | GlobeNewswire (USA) | ||
| CROSSJECT Aktie jetzt für 0€ handeln | |||||
| 09.12.24 | Crossject and the U.S. Department of Defense Relaunch Joint Research on Needle-free Autoinjectors, Extending Their Cooperative Research and Development Agreement | 1 | GlobeNewswire (USA) | ||
| 13.11.24 | Crossject's ZENEO Auto-Injector's usability further demonstrated in extreme HAZMAT conditions | 1 | GlobeNewswire (USA) | ||
| 22.10.24 | Crossject reports strong manufacturing progress with its epilepsy rescue therapy ZEPIZURE ahead of filing U.S. Emergency Use Authorization | 111 | GlobeNewswire (Europe) | Product batch announced in July yielded new regulatory stability data. These results will directly support the requested 6-month stability data in the first quarter of 2025Crossject expects to file... ► Artikel lesen | |
| 26.09.24 | Crossject announces its eligibility for France's PEA-PME investment scheme | 1 | GlobeNewswire (USA) | ||
| 23.09.24 | Crossject reports financial results and business highlights for the first six months of 2024 | 219 | GlobeNewswire (Europe) | Available cash €5.95 million, up from €2.3 million on December 31, 2023Reports stable investments in R&D and consolidation of operating income from BARDACompany on track to successfully file for the... ► Artikel lesen | |
| 17.09.24 | Crossject to report first-half 2024 financial results and host webcast on September 23, 2024 | 1 | GlobeNewswire (USA) | ||
| 19.08.24 | Crossject appoints Tony Tipton as U.S. Chief Operating Officer in Preparation for Commercialization of ZEPIZURE Epilepsy Rescue Treatment | 217 | GlobeNewswire (Europe) | Press Release Crossject appoints Tony Tipton as U.S. Chief Operating Officer in Preparation for Commercialization of ZEPIZURE® Epilepsy Rescue Treatment Experienced executive to lead preparations... ► Artikel lesen | |
| 18.07.24 | Crossject achieves key ZEPIZURE manufacturing milestone | 156 | GlobeNewswire (Europe) | Successful completion of an additional Registration Batch of ZEPIZURE® at new manufacturing siteMilestone complements the satisfying results from previous batches under stability studies, and is... ► Artikel lesen | |
| 10.07.24 | Crossject is awarded a 6.9 million euros financing from the French Government, as part of the France 2030 innovation plan, to accelerate the development of ZENEO Epinephrine | 177 | GlobeNewswire (Europe) | Key contribution to the acceleration of the development of ZENEO® EpinephrineFinancial support includes mainly grants, as well as subsidized loansFrance 2030 Plan dedicated to supporting French companies... ► Artikel lesen | |
| 26.06.24 | Crossject elaborates on ZEPIZURE potential in light of landmark RAMPART study and its own, recently published, bioequivalence study | 216 | GlobeNewswire (Europe) | Landmark RAMPART study established midazolam intramuscular (IM) injection as a standard of care in the pre-hospital emergency management of epilepsy crises compared to traditional benzodiazepine... ► Artikel lesen | |
| 12.06.24 | Crossject appoints Dan Chiche, MD as Chief Medical Officer North America | 226 | GlobeNewswire (Europe) | Brings extensive experience in drug development in the U.S and internationally and in maximizing value of medical productsReinforces leadership team and expands presence in North AmericaSupports processes... ► Artikel lesen | |
| 14.05.24 | XFRA CAPITAL ADJUSTMENT INFORMATION - 14.05.2024 | 732 | Xetra Newsboard | Das Instrument 3W1 SE0000236382 CONCEJO AB (PUBL) B SK 5 EQUITY wird ex Kapitalmassnahme gehandelt am 14.05.2024 The instrument 3W1 SE0000236382 CONCEJO AB (PUBL) B SK 5 EQUITY is traded ex capital... ► Artikel lesen | |
| 25.04.24 | Crossject reports audited financial results for 2023 | 211 | GlobeNewswire (Europe) | Dijon, France April 25, 2024 -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharmaceuticals company developing products for emergency situations harnessing its proprietary needle-free... ► Artikel lesen | |
| 08.04.24 | XFRA 74C: WIEDERAUFNAHME/RESUMPTION | 254 | Xetra Newsboard | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| 02.04.24 | Crossject advances in its U.S. Strategy and reports Financial Results for 2023 | 297 | GlobeNewswire (Europe) | Increase in visibility in its regulatory and commercialization prospects in the U.S. since latest interactions with the FDAExpectation to receive U.S. Emergency Use Authorization (EUA) for ZEPIZURE®... ► Artikel lesen | |
| 02.04.24 | XFRA 74C: AUSSETZUNG/SUSPENSION | 161 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILCROSSJECT SA EO... ► Artikel lesen |
Seite:
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FRESENIUS | 36,560 | +0,05 % | EQS-PVR: Fresenius SE & Co. KGaA: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Stimmrechtsmitteilung: Fresenius SE & Co. KGaA
Fresenius SE & Co. KGaA: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
19.02.2025 /... ► Artikel lesen | |
| INTUITIVE SURGICAL | 545,60 | 0,00 % | Aktie von Intuitive Surgical deutlich im Minus (540,00 €) | Zu den großen Verlierern am Aktienmarkt zählt am Dienstag das Wertpapier von Intuitive Surgical . Der Kurs des Papiers sackt kräftig ab. Ein Abschlag von 4,42 Prozent zeigt die Kurstafel für die Aktie... ► Artikel lesen | |
| SERNOVA BIOTHERAPEUTICS | 0,137 | +4,26 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 13.02.2025 | Das Instrument PSH0 CA81752F1062 SERNOVA BIOTHERAPEUTICS EQUITY hat seinen ersten Handelstag am 13.02.2025: CONTINUOUS TRADING WITH AUCTIONS, PAG NAM0, SettlCurr EUR, CCP Y
The instrument PSH0 CA81752F1062... ► Artikel lesen | |
| FAMICORD | 4,180 | +0,48 % | Vita 34 firmiert um: Neuer Name FamiCord AG | Die Vita 34 AG firmiert ab sofort unter dem Namen FamiCord AG. Der neue Name basiert auf der bekanntesten Konzernmarke und soll die Expansion des Leipziger Unternehmens in weitere Geschäftsfelder unterstützen.... ► Artikel lesen | |
| GERATHERM MEDICAL | 3,680 | +2,79 % | Geratherm Medical Aktie: Fortschritte führen zum Erfolg! | Die Geratherm Medical AG, ein Spezialist für medizinische Temperaturmesstechnik, verzeichnet einen vielversprechenden Jahresbeginn 2025. Der Aktienkurs des Unternehmens stieg am 17. Januar auf 3,68... ► Artikel lesen | |
| ALIGN TECHNOLOGY | 177,65 | +0,14 % | Align Technology To Complete Buyback Program With $225 Mln Stock Repurchase | ||
| NUGEN MEDICAL DEVICES | 0,050 | -3,10 % | Unglaubliche News! Der Super-CEO der alle Türen öffnen kann! | ||
| PLUS THERAPEUTICS | 1,164 | +6,99 % | XFRA DIVERSE INSTRUMENTE: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILCASTOR MARITIME... ► Artikel lesen | |
| CARDINAL HEALTH | 121,55 | 0,00 % | Cardinal Health Inc Q2 Profit Increases, Beats Estimates | WASHINGTON (dpa-AFX) - Cardinal Health Inc (CAH) revealed a profit for its second quarter that increased from last year and beat the Street estimates.The company's earnings totaled $400 million... ► Artikel lesen | |
| RESMED | 218,70 | -2,63 % | What Are Wall Street Analysts' Target Price for ResMed Stock? | ||
| ATOSSA THERAPEUTICS | 0,732 | -2,40 % | ATOSSA THERAPEUTICS, INC. - 8-K, Current Report | ||
| DAVITA | 134,75 | -0,88 % | DaVita-Aktie mit Kursverlusten (142,1692 €) | An der US-amerikanischen Börse notiert das Wertpapier von DaVita aktuell leichter. Zuletzt zahlten Investoren für die Aktie 148,49 US-Dollar. Der Anteilsschein von DaVita verzeichnet gegenwärtig ein... ► Artikel lesen | |
| MEDICLIN | 2,900 | -0,68 % | Mediclin erhöht Prognose - Aktie stark im Plus | Die Mediclin AG hat am Dienstag ihre Prognose für das Geschäftsjahr 2024 angehoben. Das erwartete Konzern-EBIT wurde auf eine Spanne von 48,0 bis 54,0 Millionen Euro erhöht, nachdem zuvor 33,0 bis 39... ► Artikel lesen | |
| UNIDOC HEALTH | 0,290 | -0,68 % | UniDoc Health Corp.: UniDoc - Announces Filing of Amended and Restated Interim Management Discussion and Analysis | VANCOUVER, BC / ACCESS Newswire / February 24, 2025 / UniDoc Health Corp. (CSE:UDOC)(FRA:L7T)(OTCQB:UDOCF) ("UniDoc" or the "Company"), is issuing this news release to advise its shareholders that the... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Biosciences Announces Financial Results for the Third Quarter of 2024 | - Improved loss from operations by 31% -
- Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health... ► Artikel lesen |
CROSSJECT SA gehört der Branche Gesundheitswesen an. Der aktuelle Kurs liegt bei 1,764 Euro und damit -3,08 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CROSSJECT SA finden Sie auf Wallstreet Online.
